Literature DB >> 1899062

Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase.

M Ohta1, Y Itagaki, N Itoh, K Hayashi, H Nishitani, K Ohta.   

Abstract

We measured with a radioimmunoassay the concentrations of carbonic anhydrase III (CA-III, EC 4.2.1.1) in sera from 68 patients with muscular dystrophy, 10 carriers of Duchenne muscular dystrophy (DMD), and 63 patients with other neurological disorders. The values obtained were compared with those for creatine kinase (CK, EC 2.7.3.2). Serum CA-III was strikingly increased in patients with DMD (mean, 274.4 micrograms/L) and congenital (Fukuyama-type) (182.8 micrograms/L) and limb-girdle (203.7 micrograms/L) dystrophies and positively correlated with the activities of CK in patients with DMD. CA-III concentration decreased with the subjects' age and the severity of the disease, similar to the tendency observed between age or severity and the concentration of CK. We found moderately increased CA-III in patients with polymyositis, myotonic dystrophy, amyotrophic lateral sclerosis, spinal progressive muscular atrophy, or Kugelberg-Welander disease and in carriers of DMD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899062

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

1.  Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.

Authors:  Yetrib Hathout; Ramya L Marathi; Sree Rayavarapu; Aiping Zhang; Kristy J Brown; Haeri Seol; Heather Gordish-Dressman; Sebahattin Cirak; Luca Bello; Kanneboyina Nagaraju; Terry Partridge; Eric P Hoffman; Shin'ichi Takeda; Jean K Mah; Erik Henricson; Craig McDonald
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

2.  Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies.

Authors:  Burcu Ayoglu; Amina Chaouch; Hanns Lochmüller; Luisa Politano; Enrico Bertini; Pietro Spitali; Monika Hiller; Eric H Niks; Francesca Gualandi; Fredrik Pontén; Kate Bushby; Annemieke Aartsma-Rus; Elena Schwartz; Yannick Le Priol; Volker Straub; Mathias Uhlén; Sebahattin Cirak; Peter A C 't Hoen; Francesco Muntoni; Alessandra Ferlini; Jochen M Schwenk; Peter Nilsson; Cristina Al-Khalili Szigyarto
Journal:  EMBO Mol Med       Date:  2014-07       Impact factor: 12.137

Review 3.  Clinical utility of serum biomarkers in Duchenne muscular dystrophy.

Authors:  Yetrib Hathout; Haeri Seol; Meng Hsuan J Han; Aiping Zhang; Kristy J Brown; Eric P Hoffman
Journal:  Clin Proteomics       Date:  2016-04-05       Impact factor: 3.988

4.  Establishment of a highly sensitive sandwich ELISA for the N-terminal fragment of titin in urine.

Authors:  Nobuhiro Maruyama; Tsuyoshi Asai; Chiaki Abe; Akari Inada; Takeshi Kawauchi; Kazuya Miyashita; Masahiro Maeda; Masafumi Matsuo; Yo-Ichi Nabeshima
Journal:  Sci Rep       Date:  2016-12-19       Impact factor: 4.379

Review 5.  Caenorhabditis elegans as a Model System for Duchenne Muscular Dystrophy.

Authors:  Rebecca A Ellwood; Mathew Piasecki; Nathaniel J Szewczyk
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 6.208

Review 6.  Proteomic profiling of the dystrophin-deficient mdx phenocopy of dystrophinopathy-associated cardiomyopathy.

Authors:  Ashling Holland; Kay Ohlendieck
Journal:  Biomed Res Int       Date:  2014-03-20       Impact factor: 3.411

7.  Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy.

Authors:  Kristin Strandberg; Burcu Ayoglu; Andreas Roos; Mojgan Reza; Erik Niks; Mirko Signorelli; Erik Fasterius; Fredrik Pontén; Hanns Lochmüller; Joana Domingos; Pierpaolo Ala; Francesco Muntoni; Annemieke Aartsma-Rus; Pietro Spitali; Peter Nilsson; Cristina Al-Khalili Szigyarto
Journal:  J Neuromuscul Dis       Date:  2020
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.